Vaxart, Inc. (VXRT) Reports 100% Survival in H5N1 Ferret Study

Vaxart, Inc. (VXRT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main co

Vaxart said it modified its BARDA funding contract via Advanced Technology International to match the current scope of its Phase 2b COVID-19 oral pill vaccine trial. Total available funding is now about $345 million, down ~$116 million after a BARDA partial termination reduced enrollment. The change releases ~$29 million to complete trial and exploratory analyses, enabling 12-month sentinel-cohort data in coming weeks and main-cohort data in 1H 2027.

Editas Medicine (EDIT) received approval to start a Phase 1/2 trial for EDIT-401, a gene-editing therapy for high cholesterol. The trial will focus on patients with Heterozygous Familial Hypercholesterolemia (HeFH). Preclinical results showed significant LDL cholesterol reductions in non-human primates. Editas expects initial data in 2027. The stock closed at $2.75, up 0.73%.

Meta and Alphabet are collaborating with the US government on a $1.8 billion AI biology initiative, with Meta contributing $300 million. The project aims to accelerate drug development using AI. Meta's stock has risen 18% in the last 6 months, with a price target of $798. Despite this initiative, Meta's core business and spending remain key drivers for its stock.

GlobalFoundries will produce silicon interposers for TSMC at its New York facility under a five-year deal. The component is crucial for AI chip communication. Shares rose 4% premarket. Production begins in early 2028. The agreement allows for future capacity expansion.

GlobalFoundries (GFS) and Taiwan Semiconductor (TSM) will jointly produce silicon interposers in the U.S. GFS shares rose 4% in premarket trading. The deal involves expanding GFS's Malta, N.Y. facility.